Retinal imaging solutions provider AEYE Health and portable retinal devices developer Optomed will launch Aurora AEYE, a diabetic retinopathy screening solution.

Aurora AEYE is a portable, artificial intelligence (AI)-powered, fully autonomous solution.

It combines AEYE Diagnostic Screening technology (AEYE-DS) with the Optomed Aurora portable handheld device.

The device allows for patient screening anywhere, be it at home or in clinics, providing immediate diagnostic results that require no human interpretation.

Aurora AEYE received the US Food and Drug Administration (FDA) clearance in April 2024.

It will be introduced at the American Diabetes Association’s 84th Scientific Session in Orlando, Florida. 

Aurora AEYE is said to be the first FDA-cleared solution of its kind.

The screening solution requires just one image per eye and delivers instant results directly on the camera screen for patients, along with diagnostic reports for healthcare providers.

Additionally, its portable, internet-connected design enables screenings in clinics, at patients’ bedsides, and in homes.

Aurora AEYE aims to transform diabetic retinopathy screening by improving accessibility and efficiency, ultimately enhancing patient outcomes, and promoting global health equity.

AEYE Health CEO Zack Dvey-Aharon said: “By introducing FDA-grade AI in a portable camera, we’re democratising early detection, making it more accessible and affordable for millions worldwide, eliminating the barriers to traditional healthcare.

“We are delighted to collaborate with Optomed and unveil this groundbreaking technology at the heart of diabetes care, the American Diabetes Association 84th Scientific Session.”

Furthermore, the diabetic retinopathy screening solution simplifies insurance reporting and closes care gaps with automatically generated diagnostic reports.

Optomed CEO Juho Himberg said: “Aurora AEYE combines our state-of-the-art portable retinal cameras with AEYE’s autonomous AI diagnostics, providing a powerful tool for healthcare providers.

“This innovation enhances patient care and addresses the critical need for more accessible diabetic retinopathy screenings, particularly in remote and home care.”

AEYE Health’s flagship product AEYE-DS is already authorised by the FDA and commercially available with a tabletop imaging device.